sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
|
CANCIDAS
|
dexamethasone
|
ADVISE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s14
|
DDI-DrugBank.d350.s14.p3
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
citalopram
|
dicumarol
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p262
|
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.
|
griseofulvin
|
ampicillin
|
NONE
|
Norgestimate_ddi.xml
|
DDI-DrugBank.d360.s1
|
DDI-DrugBank.d360.s1.p23
|
Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
|
terfenadine
|
dirithromycin
|
NONE
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s9
|
DDI-DrugBank.d522.s9.p2
|
The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
|
H2 blockers
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s12
|
DDI-DrugBank.d48.s12.p1
|
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
|
fluoxetine
|
citalopram
|
NONE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s17
|
DDI-DrugBank.d568.s17.p16
|
Antipsychotic drugs such as phenothiazines or haloperidol;
|
Antipsychotic drugs
|
haloperidol
|
NONE
|
Benztropine_ddi.xml
|
DDI-DrugBank.d390.s0
|
DDI-DrugBank.d390.s0.p1
|
THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
|
HYDROXYZINE
|
BARBITURATES
|
EFFECT
|
Hydroxyzine_ddi.xml
|
DDI-DrugBank.d308.s0
|
DDI-DrugBank.d308.s0.p3
|
Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
|
isoniazid
|
disulfiram
|
ADVISE
|
Disulfiram_ddi.xml
|
DDI-DrugBank.d19.s7
|
DDI-DrugBank.d19.s7.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
prednisolone
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p36
|
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
|
carbamazepine
|
barbiturates
|
NONE
|
Butabarbital_ddi.xml
|
DDI-DrugBank.d184.s0
|
DDI-DrugBank.d184.s0.p28
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Nizoral
|
theophylline
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p581
|
Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
|
Diphenoxylate HCl
|
MAO inhibitors
|
INT
|
Diphenoxylate_ddi.xml
|
DDI-DrugBank.d538.s1
|
DDI-DrugBank.d538.s1.p1
|
In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
|
itraconazole
|
cisapride
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s9
|
DDI-DrugBank.d165.s9.p0
|
Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
|
cyclosporine
|
carvedilol
|
MECHANISM
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s7
|
DDI-DrugBank.d269.s7.p2
|
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
|
TNF blocking agents
|
azathioprine
|
NONE
|
Abatacept_ddi.xml
|
DDI-DrugBank.d297.s2
|
DDI-DrugBank.d297.s2.p38
|
There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
|
insulin
|
diclofenac
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s11
|
DDI-DrugBank.d249.s11.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Neoral
|
Astramorph
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p747
|
therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
|
nitrates
|
captopril
|
ADVISE
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s6
|
DDI-DrugBank.d175.s6.p2
|
To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
|
delavirdine
|
VIDEX
|
ADVISE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s15
|
DDI-DrugBank.d43.s15.p1
|
Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.
|
sedatives
|
alcohol
|
NONE
|
Dezocine_ddi.xml
|
DDI-DrugBank.d461.s0
|
DDI-DrugBank.d461.s0.p7
|
Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
|
Atromid-S
|
phenytoin
|
MECHANISM
|
Clofibrate_ddi.xml
|
DDI-DrugBank.d12.s3
|
DDI-DrugBank.d12.s3.p0
|
Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
|
Carbamazepine
|
AEDs
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s10
|
DDI-DrugBank.d277.s10.p11
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
alprazolam
|
clarithromycin
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p67
|
Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
|
HEXALEN
|
cisplatin
|
EFFECT
|
Altretamine_ddi.xml
|
DDI-DrugBank.d188.s1
|
DDI-DrugBank.d188.s1.p0
|
During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
|
Ponstel
|
furosemide
|
ADVISE
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s8
|
DDI-DrugBank.d400.s8.p0
|
With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
|
Vardenafil
|
terazosin
|
EFFECT
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s29
|
DDI-DrugBank.d198.s29.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
oxolinic acid
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p33
|
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
|
aminoglycosides
|
curare-like compounds
|
NONE
|
Botulinum Toxin Type A_ddi.xml
|
DDI-DrugBank.d133.s0
|
DDI-DrugBank.d133.s0.p3
|
Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
|
rifampin
|
fludrocortisone acetate
|
MECHANISM
|
Fludrocortisone_ddi.xml
|
DDI-DrugBank.d526.s17
|
DDI-DrugBank.d526.s17.p5
|
Antiarrhythmics: amiodarone
|
Antiarrhythmics
|
amiodarone
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s8
|
DDI-DrugBank.d97.s8.p0
|
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
|
Gastrointestinal acidifying agents
|
amphetamines
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s0
|
DDI-DrugBank.d236.s0.p10
|
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
|
famotidine
|
ranitidine
|
NONE
|
Diatrizoate_ddi.xml
|
DDI-DrugBank.d293.s0
|
DDI-DrugBank.d293.s0.p26
|
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.
|
cholestyramine
|
cerivastatin
|
NONE
|
Cerivastatin_ddi.xml
|
DDI-DrugBank.d141.s5
|
DDI-DrugBank.d141.s5.p1
|
If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.
|
pentamidine
|
HIVID
|
ADVISE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s17
|
DDI-DrugBank.d263.s17.p0
|
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
|
phenobarbital
|
calcitriol
|
MECHANISM
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s2
|
DDI-DrugBank.d98.s2.p13
|
In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.
|
digoxin
|
indomethacin
|
NONE
|
Doxazosin_ddi.xml
|
DDI-DrugBank.d367.s1
|
DDI-DrugBank.d367.s1.p6
|
Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
|
flurbiprofen
|
diuretics
|
ADVISE
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s17
|
DDI-DrugBank.d529.s17.p1
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
quinolone
|
calcium
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p6
|
Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
|
tiagabine
|
phenobarbital
|
MECHANISM
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s12
|
DDI-DrugBank.d277.s12.p9
|
Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
|
antihistamines
|
alcohol
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s1
|
DDI-DrugBank.d448.s1.p0
|
In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
|
non- steroidal antiinflammatory agent
|
thiazide diuretics
|
EFFECT
|
Ethacrynic acid_ddi.xml
|
DDI-DrugBank.d414.s6
|
DDI-DrugBank.d414.s6.p2
|
Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45 (dihydroergotamine mesylate) Injection, USP.
|
Sumatriptan
|
D.H.E. 45
|
EFFECT
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s1
|
DDI-DrugBank.d410.s1.p3
|
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).
|
Angiotensin II Receptor Antagonists
|
ARB
|
NONE
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s4
|
DDI-DrugBank.d20.s4.p10
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
olanzapine
|
quetiapine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p904
|
Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.
|
azole antifungal agents
|
hypoglycemic agents
|
EFFECT
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s26
|
DDI-DrugBank.d165.s26.p0
|
Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
|
heroin
|
central nervous system depressants
|
EFFECT
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s2
|
DDI-DrugBank.d514.s2.p0
|
In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
|
prostaglandin F2alpha
|
oxytocin
|
INT
|
1113260.xml
|
DDI-MedLine.d17.s0
|
DDI-MedLine.d17.s0.p0
|
Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)
|
Aspirin
|
Nonsteroidal Antiinflammatory Drug
|
NONE
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s8
|
DDI-DrugBank.d440.s8.p0
|
Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
|
activated charcoal
|
leflunomide
|
MECHANISM
|
Leflunomide_ddi.xml
|
DDI-DrugBank.d41.s0
|
DDI-DrugBank.d41.s0.p9
|
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
|
HALDOL
|
opiates
|
EFFECT
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s3
|
DDI-DrugBank.d186.s3.p7
|
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
|
Furosemide
|
tubocurarine
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s4
|
DDI-DrugBank.d231.s4.p0
|
The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
|
cimetidine
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s11
|
DDI-DrugBank.d237.s11.p1
|
Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
|
apraclonidine
|
cardiac glycosides
|
ADVISE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s8
|
DDI-DrugBank.d224.s8.p2
|
Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
|
Ketamine
|
ketamine
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s13
|
DDI-DrugBank.d411.s13.p1
|
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
|
nevirapine
|
CANCIDAS
|
MECHANISM
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s12
|
DDI-DrugBank.d350.s12.p9
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
dicumarol
|
oxcarbazepine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p555
|
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
|
INSPRA
|
angiotensin II receptor antagonists
|
EFFECT
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s6
|
DDI-DrugBank.d20.s6.p8
|
Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
|
fluoxetine
|
aripiprazole
|
MECHANISM
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s8
|
DDI-DrugBank.d509.s8.p8
|
In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.
|
TIKOSYN
|
contraceptives
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s33
|
DDI-DrugBank.d558.s33.p4
|
Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
|
antihistamines
|
central nervous system depressants
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s1
|
DDI-DrugBank.d448.s1.p3
|
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
|
thiazides
|
vitamin D
|
EFFECT
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s5
|
DDI-DrugBank.d384.s5.p0
|
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
|
carbamazepine
|
anticonvulsant
|
NONE
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s7
|
DDI-DrugBank.d187.s7.p20
|
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
Furosemide
|
NSAIDs
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s10
|
DDI-DrugBank.d328.s10.p0
|
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
|
alosetron
|
telithromycin
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s10
|
DDI-DrugBank.d364.s10.p1
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
Vitamin D2
|
Calcitriol
|
NONE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s0
|
DDI-DrugBank.d98.s0.p8
|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
|
norepinephrine
|
monoamine oxidase inhibitors
|
EFFECT
|
Chloroprocaine_ddi.xml
|
DDI-DrugBank.d110.s0
|
DDI-DrugBank.d110.s0.p9
|
Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
|
Aspirin
|
aspirin
|
NONE
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s4
|
DDI-DrugBank.d219.s4.p1
|
In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
|
CASODEX
|
warfarin
|
MECHANISM
|
Bicalutamide_ddi.xml
|
DDI-DrugBank.d266.s0
|
DDI-DrugBank.d266.s0.p1
|
The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
insulin
|
progestogens
|
NONE
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s2
|
DDI-DrugBank.d527.s2.p12
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
enflurane
|
antibiotics
|
NONE
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p12
|
Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
|
aluminum
|
antacids
|
NONE
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s5
|
DDI-DrugBank.d516.s5.p4
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
quinidine
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p14
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
MAOI
|
Ethanol
|
NONE
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p34
|
Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
|
ACTH
|
amphotericin B
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s2
|
DDI-DrugBank.d318.s2.p5
|
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
|
Amprenavir
|
rifabutin
|
MECHANISM
|
11158747.xml
|
DDI-MedLine.d3.s7
|
DDI-MedLine.d3.s7.p0
|
On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
|
bexarotene
|
gemfibrozil
|
NONE
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s2
|
DDI-DrugBank.d467.s2.p3
|
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
|
DOSTINEX
|
phenothiazines
|
ADVISE
|
Cabergoline_ddi.xml
|
DDI-DrugBank.d282.s0
|
DDI-DrugBank.d282.s0.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
doxycycline
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p596
|
Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
|
MIDAMOR
|
non-steroidal anti-inflammatory agents
|
ADVISE
|
Amiloride_ddi.xml
|
DDI-DrugBank.d356.s5
|
DDI-DrugBank.d356.s5.p0
|
Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
|
PRECEDEX
|
anesthetics
|
EFFECT
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s1
|
DDI-DrugBank.d197.s1.p26
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
amikacin
|
pentamidine
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p32
|
Therefore, the combination of ketoprofen and probenecid is not recommended.
|
ketoprofen
|
probenecid
|
ADVISE
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s20
|
DDI-DrugBank.d499.s20.p0
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
antipsychotic drug
|
antiparkinsonian drug
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p1
|
Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.
|
Maalox
|
gabapentin
|
MECHANISM
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s37
|
DDI-DrugBank.d438.s37.p5
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
amitriptyline
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p4
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
clobazam
|
delavirdine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p297
|
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
|
beta-blocker
|
reserpine
|
ADVISE
|
Carteolol_ddi.xml
|
DDI-DrugBank.d502.s1
|
DDI-DrugBank.d502.s1.p0
|
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.
|
indinavir
|
didanosine
|
MECHANISM
|
11120981.xml
|
DDI-MedLine.d79.s1
|
DDI-MedLine.d79.s1.p0
|
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
|
Proquin XR
|
omeprazole
|
NONE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s12
|
DDI-DrugBank.d123.s12.p9
|
No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
|
clindamycin
|
clofibrate
|
NONE
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s13
|
DDI-DrugBank.d345.s13.p17
|
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
|
dextran
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s2
|
DDI-DrugBank.d488.s2.p20
|
Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.
|
Rifampin
|
CYP3A4
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s47
|
DDI-DrugBank.d143.s47.p2
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
contraceptives
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p16
|
Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
|
antacid
|
TIKOSYN
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s32
|
DDI-DrugBank.d558.s32.p59
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
doxycycline
|
rifampin
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p53
|
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
|
halogenated hydrocarbon anesthetics
|
dopamine
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s8
|
DDI-DrugBank.d325.s8.p4
|
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
|
tetracyclines
|
iron
|
MECHANISM
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s2
|
DDI-DrugBank.d500.s2.p4
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
foscarnet
|
pentamidine
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p39
|
Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
|
alcohol
|
ethchlorvynol
|
EFFECT
|
Ethchlorvynol_ddi.xml
|
DDI-DrugBank.d405.s1
|
DDI-DrugBank.d405.s1.p2
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.